Research indicates that sotatercept effectively reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension. This discovery could inform future therapeutic strategies for managing this condition.
sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension
Original title: “Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension.”